2021H1: A collection of R&D expenses of domestic and foreign pharmaceutical companies

R&D expenses of some domestic listed pharmaceutical companies in the first half of 2021

R&D expenses of some domestic listed pharmaceutical companies in the first half of 2021

Innovation is the sail, R&D is the first

Data source: Interim report of listed companies; Compilation of pharmaceutical affairs (China Biopharmaceuticals was previously estimated)

(1 Hong Kong dollar = 0.

The R&D expenditures of domestic pharmaceutical companies in the first half of the year showed the following characteristics:

The R&D expenditures of domestic pharmaceutical companies in the first half of the year showed the following characteristics:

1.

1.

2.

2.

Hansen Pharmaceutical

In the first half of 2021, Huadong Medicine invested 536 million yuan in R&D in the pharmaceutical industry, a year-on-year increase of 6.

Huadong Medicine

3.

3.

In the first half of the year, Cinda Bio's revenue surged 97% to 1.

GenScript's revenue in the first half of the year was 1.

The R&D expenditures of Hutchison Pharmaceuticals and Simcere Pharmaceuticals also maintained growth, with R&D expenditures of the two companies increasing by 52% and 38% respectively year-on-year

4.

4.

Summarize

From the perspective of top20 R&D expenditure in the first half of the year, domestic pharmaceutical companies are increasing their innovation efforts

In the context of continuous changes in the pharmaceutical industry policy, the old pharmaceutical market structure is being broken, and a new structure is gradually being established, which promotes the high-quality development of generic drugs and encourages rapid improvement in drug R&D and innovation

Top 15 R&D Expenses of Multinational Pharmaceutical Companies in the First Half of 2021

Top 15 R&D Expenses of Multinational Pharmaceutical Companies in the First Half of 2021

Innovation is the main theme that travels through the times, and it is also an important starting point for pharmaceutical companies to stay ahead
.

Innovating is not a simple treat for dinner, it requires continuous investment in a large amount of research and development expenses.
The reason why multinational pharmaceutical companies can remain invincible for a long time is that in addition to a strong sales network and acquisition of new resources through mergers and acquisitions, the core competitiveness is Maintain the ability to innovate and evolve, and continue to introduce new products that meet market needs
.
Recently, the interim reports of multinational pharmaceutical companies have been disclosed.
We have compiled relevant data and ranked as follows according to R&D expenses:

Data sources; announcements Pharmaceutical Affairs

(Johnson & Johnson R&D accounted for 26.
5% of pharmaceutical business revenue; 1 Euro = 1.
1707 US dollars; 1 Swiss franc = 1.
091 US dollars; 1 British pound = 1.
3648 US dollars)

Data source; Announcement Pharmaceutical Affairs (Takeda’s financial reporting cycle is inconsistent, so it is not in the ranking)

Roche ranked first, with R&D expenses of US$7.
758 billion in the first half of the year, a year-on-year increase of 16%; revenue was US$33.
5 billion, and R&D expenses accounted for 23% of revenue
.

Source: Roche Announcement Pharmaceutical Affairs (1 Swiss franc = 1.
091 US dollars)

According to statistics from Guosheng Securities, in the second quarter of this year, Roche has approved 3 listing applications (1NME+2AIs), 3 of which are in the application stage (1NME+2AIs), 5 phase III clinical trials (1NME+4AIs) and 4 IIs have been initiated.
In phase clinical trials (3NMEs+1AI), 2 new molecules entered clinical phase I, and the number of pipelines in clinical and subsequent phases reached 150 in total
.
Among them, Roche's PD-L1 monoclonal antibody Tecentriq (atezolizumab, atelizumab) was approved for multiple indications in the first half of the year
.

Picture: Roche 2021H1 newly approved products or indications

Picture: Roche 2021H1 newly approved products or indications Roche 2021H1 newly approved products or indications

Source: Roche Announcement Guosheng Securities Research Institute

Merck

Merck

Merck 2021 first half of R & D investment 67.
32 billion US dollars, an increase of 58% , which 2021Q2 R & D expenses 43.
21 billion dollars
.
The company's research and development is progressing smoothly, with 52 phase II clinical pipelines and 25 phase III clinical pipelines
.
The company continues to advance the development of its oncology product portfolio, and is expected to have more than 90 potential new indications by 2028
.

Merck 2021 first half of R & D investment 67.
32 billion US dollars, an increase of 58% , which 2021Q2 R & D expenses 43.
21 billion dollars
.

Drug K has been approved for two new indications in the past two months: In July, the US FDA approved KEYTRUDA for the treatment of locally advanced skin squamous cell carcinoma; in August, the FDA approved Keytruda in combination with the oral multi-receptor tyrosine kinase inhibitor Lenvima, first-line Treatment of adult patients with advanced renal cell carcinoma (RCC)
.

Vaccines: In July, the US FDA approved the listing of the Merck pneumococcal 15-valent conjugate vaccine Vaxneuvance for the prevention of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V in adults over 18 years of age.
, 14, 18C, 19A, 19F, 22F, 23F and 33F caused by aggressive diseases
.
Vaxneuvance was approved through a priority review process
.
Currently, this vaccine is also being reviewed by the European EMA
.

COVID-19 treatment products: Merck is fully advancing the development of oral antiviral drug molnupiravir (EIDD-2801/MK-4482)
.
In April, Merck announced that it had signed a non-exclusive voluntary license agreement for Molnupiravir (Monopiravir, MK-4482.
Ribonucleoside analogue) with a well-known Indian generic drug manufacturer
.
In June, the company announced that it had signed a procurement agreement with the US government for Molnupiravir
.

In the first half of the year, Johnson & Johnson's revenue was US$45.
633 billion, a year-on-year increase of 16.
9%, and R&D expenses were 6.
572 billion yuan, a year-on-year increase of 24%; accounting for 14.
4% of revenue
.
Business income is mainly divided into three major sectors: pharmaceuticals, medical devices and general health
.
The sales of the pharmaceutical sector in the first half of 2021 were US$ 24.
798 billion, a year-on-year increase of 13.
3% ; R&D expenses accounted for 26.
5% of pharmaceutical business revenue
.

The sales of the pharmaceutical sector in the first half of 2021 were US$ 24.
798 billion, a year-on-year increase of 13.
3% ; R&D expenses accounted for 26.
5% of pharmaceutical business revenue
.

The research and development projects cover the fields of tumor, immunity, cardiovascular, anti-infection, metabolism, nervous system, personal care, etc.
, with a total of 53 products in the late clinical stage
.

In the first half of the year, Johnson & Johnson made remarkable achievements in anti-tumor research and development:

In February, Ciltacabtageneautoleucel (cilta-cel), a CAR-T therapy targeting BCMA, submitted a marketing application to the European Medicines Agency (EMA) for the treatment of relapsed and/or refractory multiple myeloma (MM)
.
In December 2019, the FDA granted cilta-cel a breakthrough therapy qualification for the treatment of MM
.

In April, cilta-cel completed the rolling submission of a biologics license application (BLA) to the FDA for the treatment of relapsed and/or refractory multiple myeloma (MM)
.

In May, DARZALEXSC was approved in Europe for the treatment of newly diagnosed adult patients with systemic light chain (AL) amyloidosis, and was additionally approved for second-line treatment of multiple myeloma;

In June, Teclistamab (BCMA, CD3) was used as a breakthrough therapy by the FDA for relapsed or refractory multiple myeloma;

Summarize

Summarize

From the perspective of Top15, the lowest R&D expenses of multinational pharmaceutical companies in the first half of the year were 1.
3 billion U.
S.
dollars, which translates to about 8.
4 billion yuan, which is equivalent to BeiGene’s one-year R&D investment
.
On the whole, compared with the R&D investment of multinational pharmaceutical companies, there is still a big gap between domestic pharmaceutical companies, but China’s pharmaceutical industry has shifted from a strategy of imitation-oriented to innovation-oriented.
The overall R&D investment of domestic pharmaceutical companies in the future Will gradually increase
.

refer to:

refer to:

NMPA/CDE;

NMPA/CDE;

Yaorong Cloud Data Cloud Data Announcement of multinational pharmaceutical companies;

Announcement of multinational pharmaceutical companies;

Guosheng Securities;

Guosheng Securities;

Pharmaceutical matters; wait
.

Pharmaceutical matters; wait
.